Sarepta Therapeutics shares fall after earnings beat on weaker Elevidys demand

11 articles · Updated · Barron's · May 6

The stock dropped 5.3% to $21.34 after hours, despite adjusted earnings of $2.88 a share and $730.8 million in revenue beating Wall Street forecasts.
Product revenue fell 46% to $330.5 million as Elevidys demand weakened, while collaboration revenue more than tripled to $400.3 million, helped by a $40 million milestone tied to Japan's launch.
Elevidys sales have been hit by 2025 safety events and a label restriction to ambulatory patients aged four and older; Sarepta maintained 2026 guidance and said more than 1,300 patients had received the therapy.

With product sales plummeting, is Sarepta’s revenue beat just masking a fatal flaw in its gene therapy business model?

Amidst safety warnings and a shrinking market, can a new clinical trial truly rescue Sarepta's controversial flagship Duchenne therapy?